Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib PK with Itraconazole or Rifampin and CV Safety
NCT02253420Phase 1Completed
- Sponsor
- Bayer
- Start
- Oct 2014
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of copanlisib in solid tumor and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve from time 0 to 168 hours, Area Under the Curve and 2 more. Started Oct 2014; status: completed.
02
Drugs
copanlisib
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02253420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02253420.